Weekly Digest - October 2026

Weekly Digest - October 2026

15 October 2026: Adlai Nortye partnered with Lilly and Merck KGaA to evaluate AN4035 in combination with cetuximab

  • Adlai Nortye has entered clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA to evaluate AN4035, its investigational CEACAM5-targeted ADC, in combination with cetuximab (Erbitux) in patients with CEACAM5-enriched, RAS-addicted solid tumors. Adlai Nortye will sponsor the ongoing global phase 1 trial
  • Under the agreements, Lilly will supply cetuximab at no cost to U.S. trial sites, while Merck KGaA will provide it at no cost to sites in Australia and China. The phase 1 study will evaluate AN4035 both as monotherapy and in combination with cetuximab, assessing safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity
  • The combination addresses a key challenge in RAS-addicted cancers, including colorectal, pancreatic and lung cancers, where RAS pathway activation can drive tumor growth. Although combining EGFR and RAS inhibition is a rational therapeutic strategy, overlapping toxicities may limit systemic treatment; tumor-directed delivery of the RAS inhibitor could potentially improve the therapeutic window
  • AN4035 is a first-in-class CEACAM5-directed ADC carrying a potent pan-RAS(ON) inhibitor payload, developed using Adlai Nortye’s proprietary RASiCA platform. By delivering the inhibitor selectively to CEACAM5-expressing tumors, the ADC is designed to suppress RAS signaling while limiting exposure of normal tissues. Preclinical studies have demonstrated potent cytotoxicity and tumor regression in cancer models
  • Strategically, the collaboration brings two major pharmaceutical companies into AN4035’s clinical development, supporting evaluation of a differentiated ADC payload beyond conventional topoisomerase I and microtubule inhibitors. If successful, the approach could establish a new strategy for combining tumor-selective RAS inhibition with EGFR blockade in RAS-driven cancers

For full story click  here

Share this